Entrada Therapeutics, Inc. (TRDA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+84.8%

$9.44

vs $5.11 price

Levered DCF

$5.38

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-0.8

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-2.96×	9.82×	-75.45×	-4.85×	-10.7×	-28.51×	-5.39×
P/B	1.39×	1.5×	2.06×	1.99×	1.79×	-18.04×	-1.62×
P/S	16.73×	3.06×	3.87×	0×	0×	0×	0×
EV / EBITDA	-2.78×	8.58×	33.52×	-4.48×	-4.87×	-27.08×	-0.7×
Gross margin	83.9%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	-613.7%	22.3%	-2.5%	0.0%	0.0%	0.0%	0.0%
Net margin	-565.5%	31.1%	-5.2%	0.0%	0.0%	0.0%	0.0%
Current ratio	12.53×	11.15×	2.33×	9.55×	44.46×	11.89×	9.08×
Debt / equity	0.17×	0.14×	0.28×	0.12×	0×	0×	0×
Interest coverage	0×	0×	0×	-36.95×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-47.0%	15.3%	-2.8%	-44.5%	-17.1%	63.9%	30.0%
Return on invested capital	-43.7%	9.4%	0.6%	-40.8%	-17.1%	-66.4%	-72.5%
Return on assets	-38.1%	12.5%	-1.4%	-37.5%	-16.7%	-60.9%	-25.5%
Free cash flow yield	-30.5%	-6.9%	26.9%	-22.8%	-10.4%	-3.7%	-45.5%
Earnings yield	-33.8%	10.2%	-1.3%	-22.4%	-9.6%	-3.5%	-18.5%
Enterprise value	$385.8M	$603M	$499.4M	$403.9M	$243.5M	$709.4M	$8.3M
Net debt / EBITDA	0.28×	-0.6×	0.04×	0.21×	5.82×	1.49×	1.44×
Cash conversion cycle (days)	-167	6	17	0	0	-1,794	-2,492